Insuficiencia de la válvula tricúspide

Solicite una Consulta

Stages

After testing confirms a diagnosis of tricuspid or other heart valve disease, your healthcare team may tell you the stage of disease. Staging helps your care team plan the most appropriate treatment.

A grade describes how much blood leaks backward through the valve. The stage of heart valve disease depends on many things, including the grade, along with symptoms, disease severity, the structure of the valve or valves, and blood flow through the heart and lungs.

Heart valve disease is staged into four basic groups:

  • Stage A: At risk. Risk factors for heart valve disease are present.
  • Stage B: Progressive. Valve disease is mild or moderate. There are no heart valve symptoms.
  • Stage C: Asymptomatic severe. There are no heart valve symptoms, but the valve disease is severe.
  • Stage D: Symptomatic severe. Heart valve disease is severe and is causing symptoms.
Solicite una consulta
Diagnóstico y tratamiento
June 16, 2026

Living with insuficiencia de la válvula tricúspide?

Connect with others like you for support and answers to your questions in the Heart & Blood Health support group on Mayo Clinic Connect, a patient community.

Heart & Blood Health Discussions

pop77
Living with high calcium score

136 Replies Mon, Oct 12, 2026

teatime
Stopping Carvedilol (Coreg): When will the effects wear off?

419 Replies Sat, Sep 26, 2026

mcphee
High Coronary Calcium Score: How do others feel emotionally?

697 Replies Thu, Sep 17, 2026

See more discussions
  1. Ferri FF. Tricuspid regurgitation. In: Ferri's Clinical Advisor 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Feb. 7, 2024.
  2. Otto CM, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2021; doi:10.1016/j.jacc.2020.11.018.
  3. Otto CM. Etiology, clinical features, and evaluation of tricuspid regurgitation. https://www.uptodate.com/contents/search. Accessed Feb. 6, 2024.
  4. Phillips KA, et al. Contemporary early postoperative cone repair outcomes for patients with Ebstein anomaly. Mayo Clinic Proceedings. 2023; doi: 10.1016/j.mayocp.2022.06.009.
  5. Stress and heart health. American Heart Association. https://www.heart.org/en/healthy-living/healthy-lifestyle/stress-management/stress-and-heart-health. Accessed May 28, 2026.
  6. Libby P, et al., eds. Tricuspid, pulmonic, and multivalvular disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Feb. 7, 2024.
  7. Patlolla SH, et al. Incidence and burden of tricuspid regurgitation in patients with atrial fibrillation. Journal of the American College of Cardiology. 2022; doi:10.1016/j.jacc.2022.09.045.
  8. Otto CM. Management and prognosis of tricuspid regurgitation. https://www.uptodate.com/contents/search. Accessed Aug. 31, 2021.
  9. Life's essential 8. American Heart Association. https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8/lifes-essential-8-fact-sheet. Accessed May 28, 2026.
  10. AskMayoExpert. Tricuspid regurgitation (adults). Mayo Clinic; 2023.
  11. Silversides C, et al. Pregnancy and valve disease. https://www.uptodate.com/contents/search. Accessed Feb. 7, 2024.
  12. Medical review (expert opinion). Mayo Clinic. Feb. 8, 2024.
  13. Tricuspid valve repair and tricuspid valve replacement. Mayo Clinic. https://www.mayoclinic.org/tests-procedures/tricuspid-valve-repair-tricuspid-valve-replacement/about/pac-20385087. Accessed May 28, 2026.
  14. Lloyd-Jones DM, et al. Life's essential 8: Updating and enhancing the American Heart Association's construct of cardiovascular health: A presidential advisory from the American Heart Association. Circulation. 2022; doi:10.1161/CIR.0000000000001078.
  15. Wilson WR, et al. Prevention of Viridans group streptococcal infective endocarditis: A scientific statement from the American Heart Association. Circulation. 2021; doi:10.1161/CIR.0000000000000969.
  16. Rehan ST, et al. Transcatheter edge-to-edge repair for tricuspid regurgitation: A systematic review and meta-analysis. Current Problems in Cardiology. 2024; doi:10.1016/j.cpcardiol.2023.102055.
  17. Tang GHL, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort. Journal of the American College of Cardiology. 2025; doi:10.1016/j.jacc.2024.10.086.
  18. Heart valve disease. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/heart-valve-disease/diagnosis-treatment/drc-20353732. Accessed May 28, 2026.
  19. Fortier JH, et al. Drug-associated valvular heart diseases and serotonin-related pathways: A meta-analysis. Heart. 2019; doi:10.1136/heartjnl-2018-314403.
  20. Balata M, et al. Comparative analysis of MitraClip/TriClip and PASCAL in transcatheter tricuspid valve repair for tricuspid regurgitation: A systematic review and meta-analysis. BMC Cardiovascular Disorders. 2024; doi:10.1186/s12872-024-04201-6.
  21. Risk factor. Dorland's Medical Dictionary Online. https://www.dorlandsonline.com. Accessed Jan. 6, 2026.

Insuficiencia de la válvula tricúspide